Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Recent Pat Biotechnol ; 18(3): 241-256, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-37605394

RESUMEN

BACKGROUND: Morus nigra L. is a plant with significant potential for drug development due to the presence of numerous bioactive compounds in its various parts. OBJECTIVES: This article aims to compile the technological perspectives of Morus nigra L. towards drug development and therapeutic indications based on registered patents in databases. METHODS: The study analyzed patents published within the last five years, focusing on products derived from different parts of the Morus nigra L. plant. Patent databases such as the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), the World Intellectual Property Organization (WIPO), and the National Institute of Industrial Property Databases (INPI) were examined. RESULTS: A total of 45 patents were categorized by country of origin, type of applicant, extraction method, and therapeutic indications. China had the highest number of patent filings (43.48%), and private companies were the primary technology patent holders (38.64%). Noteworthy extraction methods included ultrasound-assisted extraction, decoction, infusion, and maceration. The most utilized plant parts were leaves (44.44%), followed by fruits (35.56%), root bark (15.56%), and stems (4.44%). The main therapeutic indications identified were the treatment of hyperglycemia and dyslipidemia (43.33%), along with digestive problems, cosmetics, nutrition, and cleaning applications. CONCLUSION: The study of patents covers discoveries and advancements often absent in scientific articles, making a review focused on this advanced information crucial for expanding existing scientific knowledge. Even if some therapies have been explored previously, patents can reveal innovative approaches and fresh perspectives that contribute to sustained scientific progress.


Asunto(s)
Morus , Bases de Datos Factuales , Propiedad Intelectual , Patentes como Asunto , Tecnología , Estados Unidos
2.
Int J Mol Sci ; 24(15)2023 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-37569487

RESUMEN

This study aimed to evaluate Attalea funifera seed oil with or without resveratrol entrapped in organogel nanoparticles in vitro against A375 human melanoma tumor cells. Organogel nanoparticles with seed oil (SON) or with resveratrol entrapped in the seed oil (RSON) formed functional organogel nanoparticles that showed a particle size <100 nm, polydispersity index <0.3, negative zeta potential, and maintenance of electrical conductivity. The resveratrol entrapment efficiency in RSON was 99 ± 1%. The seed oil and SON showed no cytotoxicity against human non-tumor cells or tumor cells. Resveratrol at 50 µg/mL was cytotoxic for non-tumor cells, and was cytotoxic for tumor cells at 25 µg/mL. Resveratrol entrapped in RSON showed a decrease in cytotoxicity against non-tumor cells and cytotoxic against tumor cells at 50 µg/mL. Thus, SON is a potential new platform for the delivery of resveratrol with selective cytotoxic activity in the treatment of melanoma.


Asunto(s)
Antineoplásicos , Arecaceae , Melanoma , Nanogeles , Sistema de Administración de Fármacos con Nanopartículas , Aceite de Palma , Resveratrol , Resveratrol/administración & dosificación , Melanoma/terapia , Humanos , Línea Celular Tumoral , Nanogeles/administración & dosificación , Nanogeles/química , Arecaceae/química , Aceite de Palma/química , Semillas/química , Tamaño de la Partícula , Antineoplásicos/administración & dosificación , Antineoplásicos/química
3.
Crit Rev Anal Chem ; 52(4): 697-711, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-32985223

RESUMEN

Dietary supplements composed by the combination of a calcium salt with cholecalciferol (vitamin D3) are widely used for improving bone health in conditions caused by the deficiency of these compounds in the body. Historically, these supplements have been linked to quality and safety issues. In the case of calcium salts, the presence of potentially toxic contaminants such as lead (Pb) has already been alerted by health authorities from different countries. Meanwhile, cholecalciferol is very unstable under inadequate manufacturing and storage conditions. The content of both compounds in commercial dietary supplements is often found to be in disagreement with the label claims, which can lead to a deficient or excessive nutrient intake by consumers. In this scenario, analyzing these compounds is still a difficult and time-consuming task, which usually requires specific pretreatment procedures and multiple analytical methods due to the inorganic nature of calcium and the organic nature of cholecalciferol. Therefore, this article reviews the analytical methods, described in official compendia and scientific literature, for the determination of calcium salts and cholecalciferol in dietary supplement formulations. We also approached the sample preparation procedures highly required due to the matrix complexity of these materials.


Asunto(s)
Calcio , Colecalciferol , Calcio de la Dieta , Suplementos Dietéticos , Sales (Química)
4.
Curr Pharm Des ; 28(5): 410-426, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34348618

RESUMEN

BACKGROUND: The oral route is the most frequently used and the most convenient route of drug administration since it has several advantages, such as ease of use, patient compliance, and better costeffectiveness. However, physicochemical and biopharmaceutical limitations of various active pharmaceutical ingredients (API) hinder suitability for this route, including degradation in the gastrointestinal tract, low intestinal permeability, and low bioavailability. To overcome these problems, while maintaining therapeutic efficacy, polymeric nanoparticles have attracted considerable attention for their ability to increase drug solubility, promote the controlled release, and improve stability. In addition, the functionalization of nanocarriers can increase uptake and accumulation at the target site of action, and intestinal absorption, making it possible to obtain more viable, safe and efficient treatments for oral administration. OBJECTIVE: This systematic review aimed to seek recent advances in the literature on the use of polymeric nanoparticles functionalization to increase intestinal permeability of APIs that are intended for oral administration. METHODS: Two bibliographic databases were consulted (PubMed and ScienceDirect). The selected publications and the writing of this systematic review were based on the guidelines mentioned in the PRISMA statement. RESULTS: Out of a total of 3036 studies, 22 studies were included in this article based on our eligibility criteria. The results were consistent for the application of nanoparticle functionalization to increase intestinal permeability. CONCLUSION: The functionalized polymeric nanoparticles can be considered as carrier systems that improve the intestinal permeability and bioavailability of APIs, with the potential to result, in the future, in the development of oral medicines.


Asunto(s)
Productos Biológicos , Nanopartículas , Administración Oral , Disponibilidad Biológica , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Humanos , Permeabilidad , Preparaciones Farmacéuticas , Polímeros/metabolismo
5.
Int J Dermatol ; 61(1): 89-98, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34510406

RESUMEN

The World Health Organization (WHO) classifies leishmaniasis as a disease for which the development of new treatments is a priority. Available drugs are not fully effective in all cases; they have parenteral administration and exhibit serious and common adverse effects. The only oral drug available (miltefosine) has shown resistance, is expensive, and is not available in many endemic countries. Thus, the development of an oral medicine may solve many of these issues. Based on that, this review aimed to investigate which therapeutic alternatives have been studied for the development of oral drugs for the treatment of cutaneous leishmaniasis. A literature search for keywords "leishmania and oral" was performed in PubMed and ScienceDirect, considering articles published in the last 5 years. The articles were selected based on the objective of the review. The main problem in the current treatment of leishmaniasis is the administration of injectables, since it requires patients to travel to health centers, hospitalization, and professional administration, conditions that are not adapted to the socioeconomic reality of patients. Therefore, many research studies have evaluated oral alternatives for the treatment of cutaneous leishmaniasis. The main tested approaches were obtaining new molecules, repositioning drugs, and new formulations of old drugs. The prospects are encouraging but still require more in vivo bioavailability and clinical trials.


Asunto(s)
Antiprotozoarios , Leishmania , Leishmaniasis Cutánea , Leishmaniasis , Antiprotozoarios/uso terapéutico , Composición de Medicamentos , Humanos , Leishmaniasis Cutánea/tratamiento farmacológico
6.
Eur J Pharm Sci ; 165: 105922, 2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34217802

RESUMEN

Layered Double Hydroxides (LDH) have received great attention in the development of drug carrier systems. LDHs have become intelligent excipients of high technological potential for the pharmaceutical industry due to their ability to intercalate biomaterials in the interlayer region, adsorb substances on its vast surface area, have flexible structure, swelling properties, high chemical and thermal stability, modulate drug release, have high biocompatibility and be easily synthesized. This article, using typical examples, mainly addresses the systems formed between LDHs and antimicrobial, antineoplastic and anti-inflammatory agents, which constitute the main pharmacological classes of wide interest due to the problems encountered with low solubility, control in administration, stability in body fluids and toxicity, among others. Additionally, the article also reports on the recent development of ternary or quaternary (multicomponent systems) compounds based on LDH, bringing the advantages of targeted therapy, improving the aqueous stability of nanohybrids and the performance of these inorganic carriers.


Asunto(s)
Antineoplásicos , Excipientes , Portadores de Fármacos , Liberación de Fármacos , Hidróxidos
7.
Drug Dev Res ; 81(7): 803-814, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32394440

RESUMEN

Considered prevalent in many countries on five continents, especially in low-income regions, leishmaniasis is a neglected tropical disease classified by World Health Organization as one of the diseases for which the development of new treatments is a priority. It is an infectious disease caused by protozoa of the genus Leishmania, whose species may cause different clinical manifestations, such as cutaneous and visceral leishmaniasis (VL). Treatment is exclusively by drug therapy, as it has not been possible to develop vaccines yet. Currently available drugs are not fully effective in all cases; they have parenteral administration and exhibit a number of serious and very common adverse effects. The only oral drug available is expensive and it is not available in many endemic countries. Injectable administration is the main problem of treatments, since it requires patients to go to health centers, hospitalization and professional administration, which are conditions that are not adapted to the reality of the poverty conditions of patients with the disease. In this context, the development of an oral medicine has become a focus as it may solve many of these issues. Based on this scenario, this review aimed to investigate which therapeutic alternatives have been studied for the development of oral drugs directed to the treatment of human VL.


Asunto(s)
Antiprotozoarios/uso terapéutico , Leishmaniasis Visceral/tratamiento farmacológico , Administración Oral , Animales , Composición de Medicamentos , Reposicionamiento de Medicamentos , Humanos
8.
Curr Pharm Des ; 26(36): 4536-4550, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32303163

RESUMEN

Chronic wounds are a remarkable cause of morbidity, requiring long-time treatments with a significant impact on the quality of life and high costs for public health. Although there are a variety of topical skin preparations commercially available, they have several limitations that frequently impair wound healing, such as drug instability, toxicity, limited time of action and ineffective skin permeation. In recent years, researchers have focused on the development of new effective treatments for wound healing and shown frequent interest in nanometric drug delivery systems to overcome such obstacles. In dermatology, lipid nanoparticles (LNPs) have received great attention from researchers due to their great functionalities, greater adhesion to the skin and film formation, enabling the hydration and maintenance of skin integrity, as well as present a more effective penetration through the skin barrier. This review provides an update on topical formulations based on Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as wound healing treatments. Both SLNs and NLCs are able to increase solubility and stability of active pharmaceutical ingredients and increase skin penetration compared to the free drugs. Additionally, SLNs and NLCs can increase pharmacological activity, increase the release profile of the drugs, promote synergistic effects and improve the sensory properties of the final formulation. Topical dosage forms containing nanoparticles have been extensively evaluated for wound healing activity, mainly the dressings, films and scaffolds. Therefore, lipid nanoparticles have contributed in improving wound healing therapies when incorporated into other dosage forms with better efficacy and lesser adverse effects than conventional formulations.


Asunto(s)
Nanopartículas , Calidad de Vida , Química Farmacéutica , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Humanos , Lípidos , Tamaño de la Partícula , Piel , Cicatrización de Heridas
9.
Int J Dermatol ; 57(8): 894-900, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29766488

RESUMEN

Skin disease is one of the most common human diseases and affects between 30% and 70% of individuals, which requires a lot of attention to their treatments. The delivery of active pharmacological ingredients at the topical level is a challenge because of the difficulties in overcoming the mechanical barrier created by the skin and reaching greater depths, since delivery specificities are decisive for the degree of effectiveness. In this way, the nanoemulsions emerge as a potential system for the incorporation of active substances in the cells and for the controlled release of active principles. The present article intends to review the main treatments for which the nanoemulsions were used in the field of dermatology. In addition, it discusses the results and advantages over the other dermatological therapies that are being used. The results showed that the particle size in nanoemulsions increased the contact surface area, resulting in increased drug efficacy, even in comparison with other existing pharmaceutical formulations. In conclusion, it has been shown that nanoemulsions have a better performance in efficacy, safety, permeability profile, and bioavailability compared with other formulations studied.


Asunto(s)
Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Emulsiones/uso terapéutico , Nanopartículas/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Antifúngicos/administración & dosificación , Antifúngicos/farmacocinética , Disponibilidad Biológica , Quimioprevención , Sistemas de Liberación de Medicamentos , Emulsiones/administración & dosificación , Emulsiones/farmacocinética , Humanos , Nanopartículas/administración & dosificación , Permeabilidad , Neoplasias Cutáneas/prevención & control
10.
Recent Pat Nanotechnol ; 12(2): 101-109, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29032764

RESUMEN

BACKGROUND: Brazil is the fourth largest personal hygiene, perfumery and cosmetics (HPPC) consumer market in the world, leading industries to invest heavily in cosmetic research. Nanotechnology is studied and applied in several branches of health and, in the cosmetic area, focuses on the effectiveness of the products, safety of use and stability of the formulation. Thus, nanoemulsions appear as an attractive option for cosmetic manufacturers. OBJECTIVE: In this context, a technological investigation was carried out, through a patent search, with the objective of verifying the current panorama of the nanoemulsions for the development of cosmetic formulations. METHOD: To do this, we consulted the Espacenet® database, using the word "nanoemulsion", associated with the IPC code "A61q19". A total of 188 patents were found, of which 118 were available for display, whose data were organized into charts for discussion. RESULT: The results show that developed countries are still the largest patent holders in the area, with the exception of South Korea, which ranked first with 39 patent applications. France appears as the most important in this research, but the largest market of interest for this technology is North America. Brazil seems to have less number of patents (3) and have not been registered in the country. CONCLUSION: The predominance of cosmetic nanoemulsions was mainly for aesthetic purposes. Nanoemulsions for cosmetic application still have potential for research and development, especially when related to raw materials of plant origin, where Brazil can be highlighted.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...